Laserfiche WebLink
not, however, consider the results of urine or other specimens that are not obtained or processed in <br />accordance with DOT regulations. <br />Results.'' The MRO will use staff under his direct supervision to handle administrative processes <br />for negative test results including receiving the iresult from the laboratory, reviewing the paperwork for <br />accuracy, and reporting of the result to the DER. <br />The MRO staff may make the initial contact with employees having confirmed positive, adulterated, <br />substituted, and invalid test results, for the purposes of setting up an interview for the MRO. The <br />MRO will personally conduct the interview with the employee to determine whether there is a <br />legitimate medical explanation for these results. This interview will be conducted, in most cases, <br />before the Company is notified. If the result is confirmed positive by the laboratory, and a legitimate <br />medical explanation is established, the MRO will report the result to the DER as negative. If not, the <br />MRO will report the result to the DER as positive. If the confirmed result is adulterated or substituted, <br />and a legitimate medical' explanatlon is established, the MRO will report the result to the DER as <br />cancelled and notify ODAPC, in accordance with Part 40 procedures. If not, the MRO will report the <br />result to the DER as a refusal to test. If the result is invalid, and an acceptable reason is established, <br />the MRO will report the result to the DER as cancelled and the process will stop, unless a negative <br />test result Is needed (e,g., pre -employment, return -to -duty and follow-up). If an acceptable reason Is <br />not established, the MRO will report the result to the DER as cancelled and order an immediate <br />recollection under direct observation. <br />Reports.s' All drug test results will be reported to the Company 'DER in a confidential and timely <br />manner. Before reporting any results, the MRO will have received a copy of the CCF showing where <br />the employee has signed the form. The time period from collecting the specimen to re -porting the <br />verified test result is generally shorter for negatives than for non -negatives. Non -negatives will not be <br />reported to the DER until all Information required for the employee interview is received and approved <br />by the MRO. The Company may use a. CITPA as Its intermediary in receiving drug test results. If so, <br />those reports will be handled in accordance with Part 40 requirements. If the MRO does not use <br />Copy 2 of the CCF for reporting results, the MRO will maintain a copy of the signed or stamped report <br />in addition to the signed or stamped and dated Copy 2. If the MRO uses an electronic data file to <br />report negatives, the MRO will maintain a retrievable copy of that report in a format suitable for <br />inspection and auditing by a DOT representative. <br />9. Split Specimen Testing <br />Split Specimen. SB When the MRO has verified a result as positive, adulterated, or substituted, the <br />MRO will notify the employee of their right to have the split specimen tested. The employee must <br />notify the MRO within 72 hours of the result being verified in order to have this testing conducted. If <br />the employee requests that the split specimen be tested within the 72-hour period, the MRO will <br />ensure that the split specimen Is tested, Testing of the split specimen is only conducted at the request <br />of the employee, and then only after using the MRO as the requesting agent for the employee. <br />The Company is responsible for making sure that the MRO, first laboratory, and second laboratory <br />perform the functions noted in Part 40 in a timely manner, once the employee has made a timely <br />request for a test of the split specimen (e.g., by establishing appropriate accounts with laboratories <br />for testing split specimens). <br />The Company must not condition compliance with these requirements on the employee's direct <br />payment to the MRO or laboratory or the employees agreement for reimbursement of the costs of <br />testing. For example, if the Company's asks the employee to pay for some or all of the cost of testing <br />the split specimen, and the employee is unwilling or unable to do so, the Company must ensure that <br />the test takes place to a timely manner, which means that the Company will pay for the split testing. <br />The Company may seek payment or reimbursement of all or part of the cost of the split specimen <br />from the employee. Part 40 takes no position on who ultimately pays the cost of the test, so long as <br />the Company ensures that the testing is conducted as required and the results released <br />appropriately. <br />Laboratory." The testing of the ,split specimen will be conducted at another HHS-certified <br />laboratory, different from, the original laboratory. The Company will select the second laboratory. The <br />split specimen will be tested for the same substance or condition that was found in the primary <br />J. RANCK ELECTRIC, INC. <br />PHMSA DRUG/ALCOHOL PLAN <br />NATIONAL COMPL IANCE MANAGEMENT SERVICE, INC. (,NCMS) - 2M 25 <br />